The partnership will move Sonoma Biotherapeutics’ Phase 1 autologous CAR-Treg therapy for treatment-resistant rheumatoid arthritis onto Cellares’ automated manufacturing and quality control systems to improve scalability, consistency, and readiness for later-stage development.
Could a gentler, more scalable method improve how cells are isolated for advanced therapies? We spoke with Bracco’s Sophie He about the early data, manufacturing potential, and challenges ahead.
The program is intended to accelerate US drug manufacturing scale-ups and address unmet patient needs. Two companies familiar to our regenerative readers, Cellares and Fujifilm Biotechnologies, made the list!
Verismo is ramping up its 2 Phase 1s targeting solid tumors and B-Cell non-Hodgkin lymphomas, selecting Cryoport for its cold chain.
The automated CDMO is hoping to reduce America's reliance on foreign biomanufacturing for advanced therapies.
The Living Knee project is hoping to replace traditional knee replacements, expected to begin Phase 1 trials around 2028.
Cell and gene therapies are advancing quickly, but the systems needed to deliver them at scale are still lagging behind. Terumo’s new Ecosystem Blueprint aims to bridge that gap in Asia-Pacific by...
Made Scientific will use RoosterBio's off-the-shelf MSCs, MSC expansion media, EV collection media, and related bioprocess expertise into its GMP operations.
The 38 projects include work in diabetes, cancer, Parkinson's disease, stroke, sickle cell disease, chronic pain, and cardiovascular, bone, blood, digestive, and neurological disorders
The company is working on iPSC-derived, AAV, and small molecule therapies for neurodegenerative, orthopedic, and blood-based disorders, with the help of OpenAI's models which seem to be accelerating life science research.
